MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
2.010
+0.040
+2.03%
After Hours: 2.007 -0.003 -0.15% 19:34 08/07 EDT
OPEN
1.980
PREV CLOSE
1.970
HIGH
2.025
LOW
1.959
VOLUME
3.70M
TURNOVER
--
52 WEEK HIGH
4.460
52 WEEK LOW
0.9842
MARKET CAP
693.76M
P/E (TTM)
-2.6165
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE) and Allogene Therapeutics (ALLO)
TipRanks · 2d ago
Weekly Report: what happened at ALLO last week (0727-0731)?
Weekly Report · 4d ago
FDA Grants RMAT, Fast Track Status To Cema-cel For High-Risk Large B-cell Lymphoma; Stock Up
NASDAQ · 07/30 08:56
Analysts’ Top Healthcare Picks: Repligen (RGEN), Allogene Therapeutics (ALLO)
TipRanks · 07/29 18:00
Allogene rises as FDA offers Fast Track, RMAT tags to cell therapy
Seeking Alpha · 07/29 17:47
Allogene gets RMAT, Fast Track designations for cemacabtagene ansegedleucel
TipRanks · 07/29 12:56
Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA's Regenerative Medicine Advanced Therapy, Fast Track Designations To Treat B-Cell Lymphoma
Benzinga · 07/29 12:32
Insider Sellers Might Regret Selling Allogene Therapeutics Shares at a Lower Price Than Current Market Value
Simply Wall St · 07/29 10:45
More
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.